NCT07585032Recruiting
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 27 Apr 2026
- Start date
- 31 Mar 2025
- Primary completion date
- Dec 2028
- Lead sponsor
- Sahlgrenska University Hospital
- NCT number
- NCT07585032
What you commit to
- Study type: Observational
- Planned participants: 20
- From 31 Mar 2025 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients unwilling to participate
- Patients unable to understand and obtain written informed conscent
- Severe comorbidity
Who the study is looking for
- Insulinoma verified by pathology (often from EUS-FNB-sampling)
Age in the registry: 15 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sahlgrenska Univeristy Hospital Coordinator of this site? Confirm its status | Gothenburg | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.